Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Muñoz-Couselo

Showing results (21-30 of 79) with videos related to

Pageof 8
Sort By:
Frontiers in Medicine|August 1, 2022
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening RateLaia Aceituno, Juan Bañares, Lourdes Ruiz-Ortega, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2024
SEOM-GEM clinical guidelines for cutaneous melanoma (2023)Iván Márquez-Rodas, Eva Muñoz Couselo, Juan F Rodríguez Moreno, et al.
Frontiers in Medicine|September 8, 2022
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practiceMònica Sabaté Gallego, Eulàlia Pérez Esquirol, Núria Garcia Doladé, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 19, 2024
Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approachEva Muñoz Couselo, Javier Cañueto, Vanessa Jerviz Guía, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Plos One|November 12, 2024
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 studyGraham Cohen, Bernardo Rapoport, Sze W Chan, et al.
Cancers|January 11, 2025
Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of RelapseSergio Martinez-Recio, Maria Alejandra Molina-Pérez, Eva Muñoz-Couselo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancerÁngela Quintana, Vicente Peg, Aleix Prat, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2024
Access to melanoma drugs in Spain: a cross-sectional surveyMaria Gonzalez-Cao, Teresa Puertolas, Jose Luis Manzano, et al.
Pageof 8

Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
Frontiers in Medicine|August 1, 2022
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening RateLaia Aceituno, Juan Bañares, Lourdes Ruiz-Ortega, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2024
SEOM-GEM clinical guidelines for cutaneous melanoma (2023)Iván Márquez-Rodas, Eva Muñoz Couselo, Juan F Rodríguez Moreno, et al.
Frontiers in Medicine|September 8, 2022
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practiceMònica Sabaté Gallego, Eulàlia Pérez Esquirol, Núria Garcia Doladé, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 19, 2024
Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approachEva Muñoz Couselo, Javier Cañueto, Vanessa Jerviz Guía, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Plos One|November 12, 2024
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 studyGraham Cohen, Bernardo Rapoport, Sze W Chan, et al.
Cancers|January 11, 2025
Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of RelapseSergio Martinez-Recio, Maria Alejandra Molina-Pérez, Eva Muñoz-Couselo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancerÁngela Quintana, Vicente Peg, Aleix Prat, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2024
Access to melanoma drugs in Spain: a cross-sectional surveyMaria Gonzalez-Cao, Teresa Puertolas, Jose Luis Manzano, et al.
Pageof 8